CIBC Asset Management’s Maravai LifeSciences MRVI Stock Holding History

CIBC Asset Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-9,982	Closed	-$255K	–	1186
2022 Q3	$255K	Sell	9,982 -40	-0.4%	-$1K	﹤0.01%	958
2022 Q2	$285K	Sell	10,022 -714	-7%	-$22.6K	﹤0.01%	907
2022 Q1	$379K	Sell	10,736 -148	-1%	-$4.96K	﹤0.01%	927
2021 Q4	$456K	Buy	10,884 +115	+1%	+$4.66K	﹤0.01%	864
2021 Q3	$529K	Sell	10,769 -3,892	-27%	-$190K	﹤0.01%	812
2021 Q2	$612K	Sell	14,661 -4,087	-22%	-$158K	﹤0.01%	773
2021 Q1	$668K	Buy	18,748 +10,538	+128%	+$349K	﹤0.01%	737
2020 Q4	$230K	Buy	+8,210	New	+$229K	﹤0.01%	1047

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

CIBC Asset Management's MRVI Position: Q4 2022 in Review

CIBC Asset Management sold out of Maravai LifeSciences (MRVI) in Q4 2022, closing a stake of 9,982 shares — an estimated $255K sold.

CIBC Asset Management first reported a position in MRVI in Q4 2020 and held it in 8 quarters. The position peaked at $668K in Q1 2021. 212 funds tracked by Wall St. Rank hold MRVI as of Q4 2022.

CIBC Asset Management reported no remaining Maravai LifeSciences position as of Q4 2022 after selling out during the quarter.
CIBC Asset Management sold 9,982 Maravai LifeSciences shares in Q4 2022, an estimated $255K.
CIBC Asset Management first reported a position in Maravai LifeSciences in Q4 2020 and held it in 8 quarters.
CIBC Asset Management's Maravai LifeSciences position peaked at $668K in Q1 2021.
212 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2022.

Based on CIBC Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.